Article
Radiology, Nuclear Medicine & Medical Imaging
Babak Fallahi, Niloufar Khademi, Najme Karamzade-Ziarati, Armaghan Fard-Esfahani, Alireza Emami-Ardekani, Saeed Farzanefar, Mohammad Eftekhari, Davood Beiki
Summary: In patient-based evaluation, both Tc-99m-PSMA SPECT/CT and Ga-68-PSMA PET/CT scans were positive in 95.45% (21/22) of patients. In region-based evaluation, Ga-68-PSMA PET/CT detected more regions compared to Tc-99m-PSMA SPECT/CT, with lower detection rates in the prostate bed being the main difference. There was a significant correlation between serum prostate-specific antigen level and disease extension detected by both modalities.
CLINICAL NUCLEAR MEDICINE
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Joseph Kabunda, Lerato Gabela, Chester Kalinda, Colleen Aldous, Venesen Pillay, Nozipho Nyakale
Summary: This prospective study found that Tc-99m-PSMA scan was comparable to Tc-99m-MDP in detecting bone metastases, but provided additional information on lymph nodal metastases and residual disease in prostate. Equivocal findings were reported in 4 patients on Tc-99m-MDP and none on Tc-99m-PSMA.
CLINICAL NUCLEAR MEDICINE
(2021)
Article
Chemistry, Medicinal
Yitian Wu, Xiaojun Zhang, Xiaojiang Duan, Xing Yang, Feng Wang, Jinming Zhang
Summary: This study evaluated the feasibility and therapeutic potential of three novel Lu-177-labeled ligands for prostate cancer treatment. The results showed that [Lu-177]Lu-PSMA-Q is a PSMA-specific ligand with significant anti-tumor effect in preclinical models, indicating the need for further clinical evaluation.
Article
Chemistry, Medicinal
Xiaohui Luan, Haoxi Zhou, Yimin Chen, Xiaojun Zhang, Mengchao Cui, Kuang Chen, Xiaodan Xu, Jinming Zhang, Baixuan Xu
Summary: In this study, a novel radiopharmaceutical, I-125-PSMA-7, was developed and evaluated for its potential use in imaging and biopsy punching of prostate cancer (PCa). The results showed that I-125-PSMA-7 had high affinity and specificity for PSMA, making it a promising radiotracer for targeted biopsy.
Article
Biochemistry & Molecular Biology
Magdalena Staniszewska, Pedro Fragoso Costa, Matthias Eiber, Jasmin M. Klose, Jasmin Wosniack, Henning Reis, Tibor Szarvas, Boris Hadaschik, Katharina Lueckerath, Ken Herrmann, Wolfgang P. Fendler, Janette Iking
Summary: Enzalutamide treatment can increase PSMA expression levels in prostate cancer cells, potentially allowing patients with low PSMA expression to become eligible for radioligand therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Yehia Omar, Noha M. Taha
Summary: Prostate cancer, the most common male cancer, is often diagnosed using PSMA-PET/CT imaging. However, limited access to (68)Gallium-labelled PSMA tracer and (18)Fluorinated-labelled PSMA tracer has led to the exploration of Tc-99m-PSMA SPECT as a potential alternative.
CLINICAL AND TRANSLATIONAL IMAGING
(2022)
Review
Oncology
Ioannis Tsechelidis, Alexis Vrachimis
Summary: PSMA PET, the latest nuclear medicine development, is regarded as the most promising tool for the diagnosis and treatment of prostate malignancy. However, there is still debate and ongoing research regarding its utility and position in guidelines, requiring further studies and trials for clarification.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Bo Li, Lili Duan, Jingqi Shi, Yunyun Han, Wei Wei, Xiaoliang Cheng, Yong Cao, Akeban Kader, Degang Ding, Xinyu Wu, Yongju Gao
Summary: This study investigated the diagnostic yield of 99mTc-HYNIC-PSMA SPECT/CT in patients with biochemically recurrent prostate cancer after radical prostatectomy. The results showed a high detection rate of 99mTc-HYNIC-PSMA SPECT/CT for prostate cancer, which was positively correlated with PSA levels and ADT.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Taisong Wang, Lingzhou Zhao, Wenli Qiao, Na Sun, Jinhua Zhao, Yan Xing
Summary: Compared with PET/CT or PET/MRI, SPECT/CT is cheaper and more readily accessible. This study found that Tc-99m-HYNIC-PSMA SPECT/CT is effective in detecting primary tumors and metastases in patients with newly diagnosed prostate cancer. The SUVmean and SUVmax of the high-risk stratification subgroups were higher than those of the low-moderate risk stratification subgroups, with sensitivities of 92%. However, neither SPECT/CT parameters nor clinicopathologic factors had high sensitivity in predicting distant metastasis.
FRONTIERS IN ONCOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Jens Cardinale, Frederik L. Giesel, Christina Wensky, Hendrik G. Rathke, Uwe Haberkorn, Clemens Kratochwil
Summary: In this study, a PSMA-targeted theranostic tandem with 99mTc/188Re was developed. The ligand PSMA-GCK01 demonstrated efficient radiolabeling with both radionuclides and comparable uptake characteristics to other ligands in cell-based assays. Animal experiments and clinical trials further confirmed the feasibility of this theranostic tandem.
JOURNAL OF NUCLEAR MEDICINE
(2023)
Review
Chemistry, Physical
He Wang, Zhangxin He, Xiao-Ang Liu, Yuhua Huang, Jianquan Hou, Weijie Zhang, Dan Ding
Summary: With the advent of precision medicine, PSMA-targeted theranostic strategies have had a significant impact on prostate cancer research. PSMA, as a specific membrane antigen target, is widely expressed in prostate cancer tissues and is correlated with tumor aggressiveness. Phototheranostics, including near-infrared fluorescence imaging, photoacoustic imaging, and photodynamic therapy, have shown great potential for PSMA-targeted treatment and diagnosis. However, there are still challenges and opportunities for the clinical translation of phototheranostics in the field of prostate cancer.
Review
Biochemistry & Molecular Biology
Sara Brunello, Nicola Salvarese, Debora Carpanese, Carolina Gobbi, Laura Melendez-Alafort, Cristina Bolzati
Summary: Prostate-specific membrane antigen (PSMA) has been proven to be an excellent target for diagnosis and therapy of prostate cancer. Radiolabeled compounds based on low molecular weight PSMA inhibitors have been developed for tumor nuclear molecular imaging. Technetium-99m (Tc-99m) remains the best option for single-photon emission tomography (SPECT) imaging, despite the development of new PET tracers.
Review
Biochemistry & Molecular Biology
Yasemin Sanli, Duygu Has Simsek, Oner Sanli, Rathan M. Subramaniam, Ayse Tuba Kendi
Summary: Lu-177-PSMA therapy shows promising clinical efficacy in patients with mCRPC, with predictors of efficacy being significant. Ongoing clinical trials, including a phase III multicenter FDA registration trial, are currently being conducted in the United States.
Article
Radiology, Nuclear Medicine & Medical Imaging
Betuel Altunay, Andreas Goedicke, Oliver H. H. Winz, Fabian Hertel, Dirk von Mallek, Levente K. K. Meszaros, Gitasha Chand, Hans-Juergen Biersack, Elmar Stickeler, Katja Krauss, Felix M. M. Mottaghy
Summary: The accurate determination of HER2 status is crucial for cancer patients receiving HER2-targeted therapy. Noninvasive techniques in molecular imaging, such as the use of RAD201, have shown promise in accurately determining HER2 status in metastatic (breast) cancer.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Review
Oncology
Maryam Hosseindokht, Hamid Bakherad, Hamed Zare
Summary: The research explores the application of nanobodies in targeting and sensing prostate cancer cells, aiming at efficient identification and elimination of cancer cells. These specialized nanobodies derived from camel heavy chain antibodies show promising potential in biosensors and cancer diagnostic kits.
CANCER CELL INTERNATIONAL
(2021)
Article
Chemistry, Multidisciplinary
Wouter J. M. Lokerse, Michiel Bolkestein, Simone U. Dalm, Alexander M. M. Eggermont, Marion de Jong, Holger Gruell, Gerben A. Koning
JOURNAL OF CONTROLLED RELEASE
(2017)
Article
Radiology, Nuclear Medicine & Medical Imaging
Marika H. Tesselaar, Thomas Crezee, Imke Schuurmans, Danny Gerrits, James Nagarajah, Otto C. Boerman, Ilse van Engen-van Grunsven, Johannes W. A. Smit, Romana T. Netea-Maier, Theo S. Plantinga
JOURNAL OF NUCLEAR MEDICINE
(2018)
Article
Radiology, Nuclear Medicine & Medical Imaging
Susanne Lutje, Danny Gerrits, Janneke D. Molkenboer-Kuenen, Ken Herrmann, Giulio Fracasso, Marco Colombatti, Otto C. Boerman, Sandra Heskamp
JOURNAL OF NUCLEAR MEDICINE
(2018)
Article
Medicine, Research & Experimental
Lieke Joosten, Maarten Brom, Hanneke Peeters, Sandra Heskamp, Martin Behe, Otto Boerman, Martin Gotthardt
MOLECULAR PHARMACEUTICS
(2018)
Article
Medicine, Research & Experimental
Reinier Hernandez, Sandra Heskamp, Mark Rijpkema, Desiree L. Bos, David M. Goldenberg, William J. McBride, Alfred Morgenstern, Frank Bruchertseifer, Weibo Cai, Otto C. Boerman
Meeting Abstract
Oncology
F. Huizing, B. A. W. Hoeben, G. Franssen, O. Boerman, S. Heskamp, J. Bussink
RADIOTHERAPY AND ONCOLOGY
(2018)
Article
Rheumatology
Tessa van der Geest, Debbie M. Roeleveld, Birgitte Walgreen, Monique M. Helsen, Tapan K. Nayak, Christian Klein, Martin Hegen, Gert Storm, Josbert M. Metselaar, Wim B. van den Berg, Peter M. van der Kraan, Peter Laverman, Otto C. Boerman, Marije I. Koenders
Article
Multidisciplinary Sciences
Stefanie M. A. Willekens, Lieke Joosten, Otto C. Boerman, Maarten Brom, Martin Gotthardt
SCIENTIFIC REPORTS
(2018)
Article
Oncology
Wanlu Cao, Jiaye Liu, Ling Wang, Meng Li, Monique M. A. Verstegen, Yuebang Yin, Buyun Ma, Kan Chen, Michiel Bolkestein, Dave Sprengers, Luc J. W. van der Laan, Michael Doukas, Jaap Kwekkeboom, Ron Smits, Maikel P. Peppelenbosch, Qiuwei Pan
Meeting Abstract
Endocrinology & Metabolism
M. Boss, I. Kusmartseva, W. Woliner-van der Weg, L. Joosten, M. Brom, M. Behe, C. J. Tack, O. C. Boerman, M. J. R. Janssen, M. Atkinson, M. Gotthardt
Meeting Abstract
Oncology
J. de Gooyer, F. Elekonawo, A. J. Bremers, O. C. Boerman, D. M. Goldenberg, J. H. de Wilt, M. Rijpkema
ANNALS OF SURGICAL ONCOLOGY
(2020)
Article
Materials Science, Biomaterials
Roel C. op 't Veld, Lieke Joosten, Onno I. van den Boomen, Otto C. Boerman, Paul Kouwer, Esther Middelkoop, Alan E. Rowan, John A. Jansen, X. Frank Walboomers, Frank A. D. T. G. Wagener
BIOMATERIALS SCIENCE
(2019)
Review
Urology & Nephrology
Marlene C. H. Hekman, Mark Rijpkema, Johan F. Langenhuijsen, Otto C. Boerman, Egbert Oosterwijk, Peter F. A. Mulders
EUROPEAN UROLOGY FOCUS
(2018)
Review
Biochemical Research Methods
Sandra Heskamp, Rene Raave, Otto Boerman, Mark Rijpkema, Victor Goncalves, Franck Denat
BIOCONJUGATE CHEMISTRY
(2017)
Meeting Abstract
Radiology, Nuclear Medicine & Medical Imaging
F. J. Huizing, B. A. W. Hoeben, S. Heskamp, J. Bussink, O. C. Boerman
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2017)